GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Cyclically Adjusted Price-to-FCF

CASI Pharmaceuticals (CASI Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CASI Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

CASI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CASI Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



CASI Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CASI Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, CASI Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/114.6694*114.6694
=0.000

Current CPI (Dec. 2023) = 114.6694.

CASI Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.345 98.600 -0.401
201406 -0.414 98.200 -0.483
201409 -0.454 98.900 -0.526
201412 -0.353 99.000 -0.409
201503 -0.373 99.900 -0.428
201506 -0.464 99.500 -0.535
201509 -0.471 100.500 -0.537
201512 -0.398 100.600 -0.454
201603 -0.374 102.200 -0.420
201606 -0.333 101.400 -0.377
201609 -0.341 102.400 -0.382
201612 -0.272 102.600 -0.304
201703 -0.260 103.200 -0.289
201706 -0.360 103.100 -0.400
201709 -0.286 104.100 -0.315
201712 -0.288 104.500 -0.316
201803 -3.472 105.300 -3.781
201806 -0.459 104.900 -0.502
201809 -0.488 106.600 -0.525
201812 -1.844 106.500 -1.985
201903 -0.572 107.700 -0.609
201906 -1.503 107.700 -1.600
201909 -0.501 109.800 -0.523
201912 -1.305 111.200 -1.346
202003 -0.469 112.300 -0.479
202006 -0.750 110.400 -0.779
202009 -1.500 111.700 -1.540
202012 -1.235 111.500 -1.270
202103 -1.160 112.662 -1.181
202106 -0.595 111.769 -0.610
202109 -0.478 112.215 -0.488
202112 -0.919 113.108 -0.932
202203 -0.473 114.335 -0.474
202206 -0.655 114.558 -0.656
202209 -0.514 115.339 -0.511
202212 -0.314 115.116 -0.313
202303 0.000 115.116 0.000
202306 0.000 114.558 0.000
202309 0.000 115.339 0.000
202312 0.000 114.669 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CASI Pharmaceuticals  (NAS:CASI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CASI Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Executives
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He director, 10 percent owner, officer: Chairman and CEO ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang officer: President 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd 10 percent owner LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski officer: Chief Medical Officer 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li 10 percent owner BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p. 10 percent owner UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc 10 percent owner 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd 10 percent owner P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren director, officer: CEO and Director 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065

CASI Pharmaceuticals (CASI Pharmaceuticals) Headlines

From GuruFocus

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

By PRNewswire PRNewswire 03-21-2023